Reports Q3 revenue $25.6M, consensus $23.64M. “We are proud to report our best quarter to date, achieving $25.6 million in revenue, an impressive 31% increase year-over-year, supported by a strong gross margin of 63.5%, record-setting net income of $1.9 million, and healthy cash flows that have grown our operating cash to $32.4 million,” said ChromaDex (CDXC) CEO Rob Fried. “These results reflect our growing financial strength and set the stage for even greater success. This quarter also marks the first sales of our Niagen+ products, and we look forward to further extending their availability to more wellness clinics as we continue to deliver innovative health solutions to our customers.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CDXC:
- Is CDXC a Buy, Before Earnings?
- ChromaDex Appoints Ozan Pamir as CFO for Future Growth
- ChromaDex appoints Ozan Pamir as CFO
- ChromaDex expands pharmaceutical-grade Niagen IV, injection offerings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
